Clearstead Trust LLC lifted its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 41,546 shares of the company’s stock after acquiring an additional 1,186 shares during the period. Johnson & Johnson accounts for approximately 2.4% of Clearstead Trust LLC’s holdings, making the stock its 8th biggest position. Clearstead Trust LLC’s holdings in Johnson & Johnson were worth $7,339,000 at the end of the most recent reporting period.
A number of other institutional investors also recently made changes to their positions in the stock. Kestra Private Wealth Services LLC raised its holdings in shares of Johnson & Johnson by 2.1% in the 4th quarter. Kestra Private Wealth Services LLC now owns 93,112 shares of the company’s stock worth $16,448,000 after purchasing an additional 1,889 shares in the last quarter. Martin Investment Management LLC raised its holdings in shares of Johnson & Johnson by 2.1% in the 4th quarter. Martin Investment Management LLC now owns 45,697 shares of the company’s stock worth $8,072,000 after purchasing an additional 926 shares in the last quarter. FAS Wealth Partners raised its holdings in shares of Johnson & Johnson by 6.6% during the fourth quarter. FAS Wealth Partners now owns 31,634 shares of the company’s stock valued at $5,588,000 after acquiring an additional 1,958 shares during the period. Mastrapasqua Asset Management Inc. raised its holdings in shares of Johnson & Johnson by 3.1% during the fourth quarter. Mastrapasqua Asset Management Inc. now owns 6,410 shares of the company’s stock valued at $1,132,000 after acquiring an additional 195 shares during the period. Finally, Keybank National Association OH raised its holdings in shares of Johnson & Johnson by 1.6% during the fourth quarter. Keybank National Association OH now owns 1,666,719 shares of the company’s stock valued at $294,426,000 after acquiring an additional 25,993 shares during the period. 67.94% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. Raymond James cut their price target on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a report on Wednesday. SVB Leerink cut their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating on the stock in a report on Friday, January 20th. Piper Sandler cut their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Finally, Atlantic Securities lowered their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating on the stock in a research report on Wednesday. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $173.00.
Johnson & Johnson Price Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.51 by $0.17. The business had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. Johnson & Johnson’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.67 EPS. On average, sell-side analysts predict that Johnson & Johnson will post 10.65 EPS for the current year.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be paid a dividend of $1.19 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a yield of 2.93%. The ex-dividend date of this dividend is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio is presently 94.56%.
Insider Activity at Johnson & Johnson
In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction dated Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.20% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 4/17 – 4/21
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation’s Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
